Yehong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yehong Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Gangjun Zong
Department of Cardiology, Wuxi Clinical College of Anhui Medical University, Wuxi, China
2 shared publications Baida Xu
The 904th Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu 214000, PR China
1 shared publication- Gangyong Wu
Department of Cardiology, The 904th Hospital of Joint Logistic Support Force of PLA, Wuxi, People’s Republic of China
1 shared publication Ke Chen
Wuxi Clinical College of Anhui Medical University Wuxi China
1 shared publicationLiang Chen
The 904th Hospital of Joint Logistic Support Force of PLA Wuxi China
1 shared publication- Liang Chen
Department of Cardiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 29 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (1) , e24156
CircSamd4: A novel biomarker for predicting vascular calcification
Background: Vascular calcification (VC) is usually associated with cardiovascular diseases (CVDs), which are one of the main causes of mortality in the world. This study aimed to analyze the expression of circular RNAs (circRNAs) in patients with VC and to evaluate biomarkers for the diagnosis of VC.Methods: Calcified human aortic endothelial cells (HAECs) and the calcification in mouse aorta were detected by qRT‐PCR. Subsequently, this was verified in the plasma of patients with coronary artery calcification (CAC). The plasma of 40 patients in the control group and 31 patients in the calcified group were detected by quantitative reverse transcription polymerase chain reaction (qRT‐PCR) to detect the level of circSamd4a in the blood. The diagnostic value was evaluated by logistic regression analysis and the working characteristics of subjects.Results: In the HAECs, the qRT‐PCR showed a significant decrease in the level of circSamd4a expression in the calcification group compared to the control group (p < 0.05). The calcified mouse aorta showed the same trend for circSamd4a expression, wherein the difference was statistically significant (p < 0.05); the expression of circSamd4a was significantly downregulated in the plasma of patients with VC (p < 0.01). The receiver operating characteristic (ROC) curves of circSamd4a in patients with VC and control group showed that the area under the curve (AUC) was 0.81 (95% CI: 0.707–0.913; p < 0.001).Conclusion: CircSamd4a showed a stable downward trend in different specimens, and had significant advantages as a biomarker for diagnosis of VC.
- 29 November 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (1) , e24156
Open AccessCircSamd4: A novel biomarker for predicting vascular calcification
Background: Vascular calcification (VC) is usually associated with cardiovascular diseases (CVDs), which are one of the main causes of mortality in the world. This study aimed to analyze the expression of circular RNAs (circRNAs) in patients with VC and to evaluate biomarkers for the diagnosis of VC.Methods: Calcified human aortic endothelial cells (HAECs) and the calcification in mouse aorta were detected by qRT‐PCR. Subsequently, this was verified in the plasma of patients with coronary artery calcification (CAC). The plasma of 40 patients in the control group and 31 patients in the calcified group were detected by quantitative reverse transcription polymerase chain reaction (qRT‐PCR) to detect the level of circSamd4a in the blood. The diagnostic value was evaluated by logistic regression analysis and the working characteristics of subjects.Results: In the HAECs, the qRT‐PCR showed a significant decrease in the level of circSamd4a expression in the calcification group compared to the control group (p < 0.05). The calcified mouse aorta showed the same trend for circSamd4a expression, wherein the difference was statistically significant (p < 0.05); the expression of circSamd4a was significantly downregulated in the plasma of patients with VC (p < 0.01). The receiver operating characteristic (ROC) curves of circSamd4a in patients with VC and control group showed that the area under the curve (AUC) was 0.81 (95% CI: 0.707–0.913; p < 0.001).Conclusion: CircSamd4a showed a stable downward trend in different specimens, and had significant advantages as a biomarker for diagnosis of VC.